Cubist's antibiotics wins fast-track designation from FDA

12/9/2012 | Mass High Tech (Boston)

The FDA granted qualified infectious disease products designation to CXA-201 and CB-315, two late-stage antibiotics from Cubist Pharmaceuticals. The designation qualifies both drugs for priority review and other considerations. CXA-201 is being developed as a first-line intravenous treatment for urinary tract infections and complicated intra-abdominal infections, while CB-315 is intended as an oral treatment for Clostridium difficile-associated diarrhea.

View Full Article in:

Mass High Tech (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ